Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients
ObjectiveWe sought to determine the impact of Type 2 Diabetes Mellitus (T2D) anti-hyperglycemic medications (A-HgM) on risk of Alzheimer’s disease (AD) and related dementias (ADRD) outcomes including vascular dementia, and non-AD dementia such as frontotemporal, Lewy body, and mixed etiology dementi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.878304/full |
| _version_ | 1811305340936912896 |
|---|---|
| author | Georgina Torrandell-Haro Georgina Torrandell-Haro Gregory L. Branigan Gregory L. Branigan Gregory L. Branigan Roberta Diaz Brinton Roberta Diaz Brinton Roberta Diaz Brinton Kathleen E. Rodgers Kathleen E. Rodgers |
| author_facet | Georgina Torrandell-Haro Georgina Torrandell-Haro Gregory L. Branigan Gregory L. Branigan Gregory L. Branigan Roberta Diaz Brinton Roberta Diaz Brinton Roberta Diaz Brinton Kathleen E. Rodgers Kathleen E. Rodgers |
| author_sort | Georgina Torrandell-Haro |
| collection | DOAJ |
| description | ObjectiveWe sought to determine the impact of Type 2 Diabetes Mellitus (T2D) anti-hyperglycemic medications (A-HgM) on risk of Alzheimer’s disease (AD) and related dementias (ADRD) outcomes including vascular dementia, and non-AD dementia such as frontotemporal, Lewy body, and mixed etiology dementias.Research Design and MethodsThis retrospective cohort study used the US-based Mariner claims dataset. 1,815,032 T2D participants 45 years and older with records 6 months prior and at least 3 years after the diagnosis of T2D were included. Claims were surveyed for a diagnosis of AD and ADRD 12 months post T2D diagnosis. A propensity score approach was used to minimize selection bias. Analyses were conducted between January 1st and February 28th, 2021.ResultsIn this cohort study A-HgM exposure was associated with decreased diagnosis of AD (RR, 0.61; 95% CI, 0.59–0.62; p < 0.001), vascular dementia (RR, 0.72; 95% CI, 0.69–0.74; p < 0.001) and non-AD dementia (RR, 0.67; 95% CI, 0.66–0.68; p < 0.001). Metformin was associated with the greatest risk reduction and insulin with the least reduction in risk compared to patients not receiving A-HgM for ADRD risk. Of interest, patients with a diagnosis of AD, while either on metformin or insulin, were older in age and predominately female, than individuals on these drugs that did not develop AD. Mean (SD) follow-up was 6.2 (1.8) years.ConclusionAfter controlling for age, sex, and comorbidities, A-HgM in patients with T2D was associated with a reduced risk of AD and ADRD. These findings provide evidence in support of T2D as a risk factor for AD and ADRD and the beneficial impact of early and effective control of hyperglycemia to mitigate risk. |
| first_indexed | 2024-04-13T08:23:43Z |
| format | Article |
| id | doaj.art-84f9adefd7074cf7b0e02ca4e222bd19 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-04-13T08:23:43Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-84f9adefd7074cf7b0e02ca4e222bd192022-12-22T02:54:33ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-05-011410.3389/fnagi.2022.878304878304Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic PatientsGeorgina Torrandell-Haro0Georgina Torrandell-Haro1Gregory L. Branigan2Gregory L. Branigan3Gregory L. Branigan4Roberta Diaz Brinton5Roberta Diaz Brinton6Roberta Diaz Brinton7Kathleen E. Rodgers8Kathleen E. Rodgers9Center for Innovation in Brain Science, University of Arizona, Tucson, AZ, United StatesDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United StatesCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ, United StatesDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United StatesMD-PhD Training Program, University of Arizona College of Medicine, Tucson, AZ, United StatesCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ, United StatesDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United StatesDepartment of Neurology, University of Arizona College of Medicine, Tucson, AZ, United StatesCenter for Innovation in Brain Science, University of Arizona, Tucson, AZ, United StatesDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United StatesObjectiveWe sought to determine the impact of Type 2 Diabetes Mellitus (T2D) anti-hyperglycemic medications (A-HgM) on risk of Alzheimer’s disease (AD) and related dementias (ADRD) outcomes including vascular dementia, and non-AD dementia such as frontotemporal, Lewy body, and mixed etiology dementias.Research Design and MethodsThis retrospective cohort study used the US-based Mariner claims dataset. 1,815,032 T2D participants 45 years and older with records 6 months prior and at least 3 years after the diagnosis of T2D were included. Claims were surveyed for a diagnosis of AD and ADRD 12 months post T2D diagnosis. A propensity score approach was used to minimize selection bias. Analyses were conducted between January 1st and February 28th, 2021.ResultsIn this cohort study A-HgM exposure was associated with decreased diagnosis of AD (RR, 0.61; 95% CI, 0.59–0.62; p < 0.001), vascular dementia (RR, 0.72; 95% CI, 0.69–0.74; p < 0.001) and non-AD dementia (RR, 0.67; 95% CI, 0.66–0.68; p < 0.001). Metformin was associated with the greatest risk reduction and insulin with the least reduction in risk compared to patients not receiving A-HgM for ADRD risk. Of interest, patients with a diagnosis of AD, while either on metformin or insulin, were older in age and predominately female, than individuals on these drugs that did not develop AD. Mean (SD) follow-up was 6.2 (1.8) years.ConclusionAfter controlling for age, sex, and comorbidities, A-HgM in patients with T2D was associated with a reduced risk of AD and ADRD. These findings provide evidence in support of T2D as a risk factor for AD and ADRD and the beneficial impact of early and effective control of hyperglycemia to mitigate risk.https://www.frontiersin.org/articles/10.3389/fnagi.2022.878304/fulltype 2 diabetesAlzheimer’s diseasevascular dementiaanti-hyperglycemic agentsrisk analyses |
| spellingShingle | Georgina Torrandell-Haro Georgina Torrandell-Haro Gregory L. Branigan Gregory L. Branigan Gregory L. Branigan Roberta Diaz Brinton Roberta Diaz Brinton Roberta Diaz Brinton Kathleen E. Rodgers Kathleen E. Rodgers Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients Frontiers in Aging Neuroscience type 2 diabetes Alzheimer’s disease vascular dementia anti-hyperglycemic agents risk analyses |
| title | Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients |
| title_full | Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients |
| title_fullStr | Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients |
| title_full_unstemmed | Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients |
| title_short | Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer’s Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients |
| title_sort | association between specific type 2 diabetes therapies and risk of alzheimer s disease and related dementias in propensity score matched type 2 diabetic patients |
| topic | type 2 diabetes Alzheimer’s disease vascular dementia anti-hyperglycemic agents risk analyses |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.878304/full |
| work_keys_str_mv | AT georginatorrandellharo associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT georginatorrandellharo associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT gregorylbranigan associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT gregorylbranigan associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT gregorylbranigan associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT robertadiazbrinton associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT robertadiazbrinton associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT robertadiazbrinton associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT kathleenerodgers associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients AT kathleenerodgers associationbetweenspecifictype2diabetestherapiesandriskofalzheimersdiseaseandrelateddementiasinpropensityscorematchedtype2diabeticpatients |